End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.24 CNY | +0.45% | -2.18% | -21.13% |
Apr. 15 | Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 15 | Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023 | MT |
Sales 2021 | 48.7B 6.73B | Sales 2022 | 49.31B 6.81B | Capitalization | 15.61B 2.16B |
---|---|---|---|---|---|
Net income 2021 | 471M 65.07M | Net income 2022 | 274M 37.85M | EV / Sales 2021 | 0.18 x |
Net cash position 2021 | 7.58B 1.05B | Net Debt 2022 | 1.76B 243M | EV / Sales 2022 | 0.35 x |
P/E ratio 2021 |
33.1
x | P/E ratio 2022 |
52.7
x | Employees | 2,098 |
Yield 2021 |
0.15% | Yield 2022 |
3.48% | Free-Float | 31.71% |
1 day | +0.45% | ||
1 week | -2.18% | ||
Current month | -9.31% | ||
1 month | -12.16% | ||
3 months | -17.34% | ||
6 months | -27.74% | ||
Current year | -21.13% |
Managers | Title | Age | Since |
---|---|---|---|
Wen Xia Zhou
CEO | Chief Executive Officer | 52 | 20-05-25 |
Jian Qiang Shen
CHM | Chairman | 52 | 96-05-31 |
Da Li Chen
DFI | Director of Finance/CFO | 57 | 20-05-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yi Qian Liu
CHM | Chairman | 61 | 15-03-10 |
Yunhua Xiao
BRD | Director/Board Member | 62 | 03-03-31 |
Da Li Chen
DFI | Director of Finance/CFO | 57 | 20-05-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.24 | +0.45% | 23 316 370 |
24-04-24 | 2.23 | +1.36% | 20,403,300 |
24-04-23 | 2.2 | -2.22% | 27,079,900 |
24-04-22 | 2.25 | -1.75% | 20,910,720 |
24-04-19 | 2.29 | -1.72% | 23,503,120 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.13% | 1.52B | |
+14.62% | 80.52B | |
+8.73% | 52.58B | |
+1.49% | 48.5B | |
+9.08% | 42.2B | |
+7.20% | 40.52B | |
+19.13% | 38.2B | |
-8.37% | 27.49B | |
-19.52% | 25.04B | |
+6.12% | 22.12B |
- Stock Market
- Equities
- 000627 Stock